对一线免疫联合化疗有反应的肺肝样腺癌：病例报告
Hepatoid Adenocarcinoma of the Lung Responsive to Frontline Combination Chemotherapy With Immunotherapy: Case Report.
作者信息
Lagos Galina G, Feldman Jarett L, Saqi Anjali, Shu Catherine A
机构信息
Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
Hematology and Oncology, Westmed Medical Group, Purchase, New York.
出版信息
JTO Clin Res Rep. 2020 Dec 16;2(2):100130. doi: 10.1016/j.jtocrr.2020.100130. eCollection 2021 Feb.
Hepatoid adenocarcinoma of the lung (HAL) is a rare extrahepatic tumor characterized by histologic features of hepatocellular carcinoma. The standard treatment for nonresectable HAL has not been established, though traditionally, these tumors have been treated with platinum-based chemotherapy. Here, we report the use of combination chemotherapy and immunotherapy in a patient presenting with metastatic HAL and an elevated alpha-fetoprotein. The patient had an excellent clinical, radiographic, and biomarker response. This case supports the use of chemoimmunotherapy, which is now the standard of care first-line treatment in NSCLC, for HAL.
肺肝样腺癌（HAL）是一种罕见的肝外肿瘤，具有肝细胞癌的组织学特征。尽管传统上这些肿瘤采用铂类化疗，但不可切除HAL的标准治疗方法尚未确立。在此，我们报告了一名出现转移性HAL且甲胎蛋白升高的患者接受联合化疗和免疫治疗的情况。该患者在临床、影像学和生物标志物方面均有出色反应。该病例支持将目前非小细胞肺癌一线治疗的标准护理方案——化疗免疫疗法用于HAL。
Zotero 插件